Artemisinin and its derivatives as a repurposing anticancer agent: What else do we need to do?

Molecules

Volumn 21, Issue 10, 2016, Pages

  Li, Zhe ^a   Li, Qin ^a   Wu, Jun ^a   Wang, Manyuan ^b   Yu, Junxian ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Anticancer Activity; Artemisinin; Clinical Trials; Repurposed; Specific Drug Delivery System

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE;

ANIMAL; CELL CYCLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HUMAN; NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ARTEMISININS; CELL CYCLE; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 84992397336     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21101331     Document Type: Review

References (102)

1. Boichuk, S.; Lee, D.J.; Mehalek, K.R.; Makielski, K.R.; Wozniak, A.; Seneviratne, D.S.; Korzeniewski, N.; Cuevas, R.; Parry, J.A.; Brown, M.F.; et al. Unbiased compound screening identifies unexpected drug sensitivitie sand novel treatment options for gastrointestinal stromal tumors. Cancer. Res. 2014, 74, 1200-1213.
2. Langley, R.E.; Rothwell, P.M. Aspirin in gastrointestinal oncology: New data on an old friend. Curr. Opin. Oncol. 2014, 26, 441-447.
3. Rothwell, P.M.; Price, J.F.; Fowkes, F.G.; Zanchetti, A.; Roncaglioni, M.C.; Tognoni, G.; Lee, R.; Belch, J.F.; Wilson, M.; Mehta, Z.; et al. Short-Term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379, 1602-1612.
4. Algra, A.M.; Rothwell, P.M. Effects of regular aspirin on long-Term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012, 13, 518-527.
5. Yiannakopoulou, E.C. Aspirin and NSAIDs for breast cancer chemoprevention. Eur. J. Cancer Prev. 2015, 24, 416-421.
6. Liu, X.; Chhipa, R.R.; Pooya, S.; Wortman, M.; Yachyshin, S.; Chow, L.M.; Kumar, A.; Zhou, X.; Sun, Y.; Quinn, B.; et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc. Natl. Acad. Sci. USA 2014, 111, E435-E444.
7. Kasznicki, J.; Sliwinska, A.; Drzewoski, J. Metformin in cancer prevention and therapy. Ann. Transl. Med. 2014, 2, 57.
8. Sonneveld, P.; Asselbergs, E.; Zweegman, S.; van der, H.B.; Kersten, M.J.; Vellenga, E.; van Marwijk-Kooy, M.; Broyl, A.; deWeerdt, O.; Lonergan, S.; et al. Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood 2015, 125, 449-456.
9. Wu, J.; Ng, J.; Christos, P.J.; Goldenberg, A.; Sparano, J.; Sung, M.W.; Hochster, H.S.; Muggia, F.M. Chronic thalidomide and chemoembolization for hepatocellular carcinoma. Oncologist 2014, 19, 1229-1330.
10. Pantziarka, P.; Bouche, G.; Meheus, L.; Sukhatme, V.; Sukhatme, V.P. Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent. Ecancermedicalscience 2014, 8, 485.
11. Armitage, J.O.; Sidner, R.D. Antitumour effect of cimetidine. Lancet 1979, 1, 882-893.
12. Zhang, X.W.; Yan, X.J.; Zhou, Z.R.; Yang, F.F.; Chen, S.J.; Chen, Z. Arsenic trioxide controls the fate of the PML-RAR- oncoprotein by directly binding PML. Science 2010, 328, 240-253.
13. Beauchamp, E.; Kosciuczuk, E.M.; Serrano, R.; Nanavati, D.; Swindell, E.P.; Viollet, B.; O'Halloran, T.V.; Altman, J.K.; Platanias, L.C. Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors. Mol. Cancer Ther. 2015, 14, 202-212.
14. Collaboration Research Group for Qinghaosu. A novel kind of sesquiterpene lactone-Artemisinin. Chin. Sci. Bullet. 1977, 22, 142.
15. Liu, J.M.; Ni, M.Y.; Zhou, W.S. Structure and reaction of qinghaosu (Arteannuin). Acta. Chimica Sinica 1979, 37, 129-141.
16. Klayman, D.L. Qinghaosu (artemisinin): An antimalarial drug from China. Science 1985, 228, 1049-1055.
17. Kakar, Q.; Sheikh, S.; Ahmed, I.; Khan, M.A.; Jamil, M.; ElMohammady, H.; Warsame, M. Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations. Acta. Trop. 2016, 164, 17-22.
18. Woerdenbag, H.J.; Moskal, T.A.; Pras, N.; Malingré, T.M.; El-Feraly, F.S.; Kampinga, H.H.; Konings, A.W. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J. Nat. Prod. 1993, 56, 849-856.
19. Efferth, T.; Sauerbrey, A.; Olbrich, A.; Gebhart, E.; Rauch, P.; Weber, H.O.; Hengstler, J.G.; Halatsch, M.E.; Volm, M.; Tew, K.D.; et al. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 2003, 64, 382-394.
20. Hou, J.; Wang, D.; Zhang, R.; Wang, H. Experimental therapy of hepatoma with artemisinin and its derivatives: In vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res. 2008, 14, 5519-5530.
21. Chen, T.; Li, M.; Zhang, R.;Wang, H. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J. Cell. Mol. Med. 2009, 13, 1358-1370.
22. Wang, Y.B.; Hu, Y.; Li, Z.; Wang, P.; Xue, Y.X.; Yao, Y.L.; Yu, B.; Liu, Y.H. Artemether combined with shRNA interference of vascular cell adhesion molecule-1 significantly inhibited the malignant biological behavior of human glioma cells. PLoS ONE 2013, 8, e60834.
23. Alcntara, D.D.; Ribeiro, H.F.; Cardoso, P.C.; Araújo, T.M.; Burbano, R.R.; Guimarães, A.C.; Khayat, A.S.; Oliveira, B.M. In vitro evaluation of the cytotoxic and genotoxic effects of artemether, an antimalarial drug, in a gastric cancer cell line (PG100). J. Appl. Toxicol. 2013, 33, 151-156.
24. Azimi Mohamadabadi, M.; Hassan, Z.M.; Zavaran, H.A.; Gholamzad, M.; Noori, S.; Mahdavi, M.; Maroof, H. Arteether exerts antitumor activity and reduces CD4+CD25+FOXP3+T-reg cells in vivo. Iran J. Immunol. 2013, 10, 139-149.
25. Ericsson, T.; Blank, A.; von Hagens, C.; Ashton, M.; Abelö, A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-Term oral administration of artesunate to patients with metastatic breast cancer. Eur. J. Clin. Pharmacol. 2014, 70, 1453-1463.
26. Tu, Y.Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 2011, 17, 1217-1220.
27. Zhu, D.Y.; Deng, D.A.; Zhang, S.G.; Xu, R.S. Structure of artemisilactone. Acta Chimica Sinica 1984, 48, 937-939.
28. Gravett, A.M.; Liu, W.M.; Krishna, S.; Chan, W.C.; Haynes, R.K.; Wilson, N.L.; Dalgleish, A.G. In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemother Pharmacol. 2011, 67, 569-577.
29. Yang, H.; Tan, X.J. Research advance in antitumor activities of artemisinin and its derivatives. Zhong Guo Yi Xue Ke Xue Yuan Xue Bao 2013, 35, 466-471.
30. Chow, L.M.; Chan, T.H. Novel classes of dimer antitumour drug candidates. Curr. Pharm. Des. 2009, 15, 659-674.
31. Kong, R.; Jia, G.; Chen, Z.X.; Wang, Y.W.; Mu, M.; Wang, S.J.; Pan, S.H.; Gao, Y.; Jian, H.C.; Dong, D.L.; et al. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. PLoS ONE 2012, 7, e37222.
32. Berdelle, N.; Nikolova, T.; Quiros, S.; Efferth, T.; Kaina, B. Artesunateinduces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol. Cancer Ther. 2011, 10, 2224-2233.
33. Mercer, A.E.; Copple, I.M.; Maggs, J.L.; O'Neill, P.M.; Park, B.K. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J. Biol. Chem. 2011, 286, 987-996.
34. Efferth, T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 2006, 7, 407-421.
35. Nakase, I.; Gallis, B.; Takatani-Nakase, T.; Oh, S.; Lacoste, E.; Singh, N.P.; Goodlett, D.R.; Tanaka, S.; Futaki, S.; Lai, H.; Sasaki, T. Transferrin receptor-dependent cytotoxicity of artemisinin-Transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett. 2009, 274, 290-298.
36. Lu, J.J.; Meng, L.H.; Cai, Y.J.; Chen, Q.; Tong, L.J.; Lin, L.P.; Ding, J. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-Activated protein kinase activation but independent of reactive oxygen species. Cancer Biol. Ther. 2008, 7, 1017-1023.
37. Chan, H.W.; Singh, N.P.; Lai, H.C. Cytotoxicity of dihydroartemisinin toward Molt-4 cells attenuated by N-Tert-butyl-phenylnitrone and deferoxamine. Anticancer Res. 2013, 33, 4389-4393.
38. Jiang, Z.; Chai, J.; Chuang, H.H.; Li, S.; Wang, T.; Cheng, Y.; Chen, W.; Zhou, D. Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells. Anticancer Drugs. 2012, 23, 606-613.
39. Chen, G.; Gong, R.; Shi, X.; Yang, D.; Zhang, G.; Lu, A.; Yue, J.; Bian, Z. Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. Oncotarget 2016.
40. Willoughby, J.A., Sr.; Sundar, S.N.; Cheung, M.; Tin, A.S.; Modiano, J.; Firestone, G.L. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J. Biol. Chem. 2009, 284, 2203-2213.
41. Chen, K.; Shou, L.M.; Lin, F.; Duan, W.M.; Wu, M.Y.; Xie, X.; Xie, Y.F.; Li, W.; Tao, M. Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. Eur. J. Haematol. 2013, 91, 339-346.
42. Steinbröck, L.; Pereira, G.; Efferth, T. Effects of artesunate on cytokinesis and G0/M cell cycle progression of tumour cells and budding yeast. Cancer Geno. Proteom. 2010, 7, 337-346.
43. Wang, S.J.; Gao, Y.; Chen, H.; Kong, R.; Jiang, H.C.; Pan, S.H.; Xue, D.B.; Bai, X.W.; Sun, B. Dihydroartemisinin inactivates NF-B and potentiates the anti-Tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett. 2010, 293, 99-108.
44. Cheng, R.; Li, C.; Li, C.; Wei, L.; Li, L.; Zhang, Y.; Yao, Y.; Gu, X.; Cai, W.; Yang, Z.; et al. The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells. Investig. Ophthalmol. Vis. Sci. 2013, 54, 3400-3409.
45. Li, S.; Xue, F.; Cheng, Z.; Yang, X.;Wang, S.; Geng, F.; Pan, L. Effect ofartesunateon inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NF-B p65. Int. J. Hematol. 2009, 90, 513-521.
46. Zeng, Q.P.; Zhang, P.Z. Artesunatemitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. Nitric Oxide 2011, 24, 110-112.
47. Yang, N.D.; Tan, S.H.; Ng, S.; Shi, Y.; Zhou, J.; Tan, K.S.;Wong, W.S.; Shen, H.M. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J. Biol. Chem. 2014, 289, 33425-33441.
48. Zhou, C.; Pan, W.; Wang, X.P.; Chen, T.S. Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. J. Cell. Physiol. 2012, 227, 3778-3786.
49. Hamacher-Brady, A.; Stein, H.A.; Turschner, S.; Toegel, I.; Mora, R.; Jennewein, N.; Efferth, T.; Eils, R.; Brady, N.R. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J. Biol. Chem. 2011, 286, 6587-6601.
50. Ji, Y.; Zhang, Y.C.; Pei, L.B.; Shi, L.L.; Yan, J.L.; Ma, X.H. Anti-Tumor effects of dihydroartemisinin on human osteosarcoma. Mol. Cell. Biochem. 2011, 351, 99-108.
51. Holien, T.; Olsen, O.E.; Misund, K.; Hella, H.; Waage, A.; Rø, T.B.; Sundan, A. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate. Eur. J. Haematol. 2013, 91, 339-346.
52. Jiao, Y.; Ge, C.M.; Meng, Q.H.; Cao, J.P.; Tong, J.; Fan, S.J. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol. Sin. 2007, 28, 1045-1056.
53. Chen, H.; Sun, B.; Wang, S.; Pan, S.; Gao, Y.; Bai, X.; Xue, D. Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: Involvement of cell cycle arrest and inactivation of nuclear factor-B. J. Cancer Res. Clin. Oncol. 2010, 136, 897-903.
54. Lu, J.J.; Meng, L.H.; Shankavaram, U.T.; Zhu, C.H.; Tong, L.J.; Chen, G.; Lin, L.P.; Weinstein, J.N.; Ding, J. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem. Pharmacol. 2010, 80, 22-30.
55. Blazquez, A.G.; Fernandez-Dolon, M.; Sanchez-Vicente, L.; Maestre, A.D.; Gomez-San, M.A.B.; Alvarez, M.; Serrano, M.A.; Jansen, H.; Efferth, T.; Marin, J.J.; et al. Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. Bioorg. Med. Chem. 2013, 21, 4432-4441.
56. Efferth, T.; Romero, M.R.; Wolf, D.G.; Stamminger, T.; Marin, J.J.; Marschall, M. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 2008, 47, 804-811.
57. Romero, M.R.; Efferth, T.; Serrano, M.A.; Castaño, B.; Macias, R.I.; Briz, O.; Marin, J.J. Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. Antiviral. Res. 2005, 68, 75-83.
58. Ooko, E.; Saeed, M.E.; Kadioglu, O.; Sarvi, S.; Colak, M.; Elmasaoudi, K.; Janah, R.; Greten, H.J.; Efferth, T. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 2015, 22, 1045-1054.
59. Mu, D.; Chen, W.; Yu, B.; Zhang, C.; Zhang, Y.; Qi, H. Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells. Methods Find Exp. Clin. Pharmacol. 2007, 29, 33-38.
60. Mu, D.; Zhang, W.; Chu, D.; Liu, T.; Xie, Y.; Fu, E.; Jin, F. The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. Cancer Chemother Pharmacol. 2008, 61, 639-645.
61. Jia, G.; Kong, R.; Ma, Z.B.; Han, B.; Wang, Y.W.; Pan, S.H.; Li, Y.H.; Sun, B. The activation of c-Jun NH2-Terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells. J. Exp. Clin. Cancer Res. 2014, 33, 8.
62. Njokah, M.J.; Kang'ethe, J.N.; Kinyua, J.; Kariuki, D.; Kimani, F.T. In vitro selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemisinin. Malar. J. 2016, 15, 381.
63. Wang, S.J.; Sun, B.; Cheng, Z.X.; Zhou, H.X.; Gao, Y.; Kong, R.; Chen, H.; Jiang, H.C.; Pan, S.H.; Xu, D.B.; et al. Dihydroartemisin in inhibits angiogenesis in pancreatic cancer by targeting the NF-B pathway. Cancer Chemother. Pharmacol. 2011, 68, 1421-1430.
64. Dong, F.; Zhou, X.; Li, C.; Yan, S.; Deng, X.; Cao, Z.; Li, L.; Tang, B.; Allen, T.D.; Liu, J. Dihydroartemisin in targets VEGFR2 via the NF-B pathway in endothelial cells to inhibit angiogenesis. Cancer Biol. Ther. 2014, 15, 1479-1488.
65. Guo, L.; Dong, F.; Hou, Y.; Cai, W.; Zhou, X.; Huang, A.L.; Yang, M.; Allen, T.D.; Liu, J. Dihydroartemisin in inhibits vascular endothelial growth factor-induced endothelial cell migration by a p38 mitogen-Activated protein kinase-independent pathway. Exp. Ther. Med. 2014, 8, 1707-1712.
66. Saeed, M.E.; Kadioglu, O.; Seo, E.J.; Greten, H.J.; Brenk, R.; Efferth, T. Quantitative structure-Activity relationship and molecular docking of artemisinin derivatives to vascular endothelial growth factor receptor 1. Anticancer Res. 2015, 35, 1929-1934.
67. Chen, H.; Shi, L.; Yang, X.; Li, S.; Guo, X.; Pan, L. Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells. Int. J. Hematol. 2010, 92, 587-597.
68. Konkimalla, V.B.; McCubrey, J.A.; Efferth, T. The role of downstream signaling pathways of the epidermal growth factor receptor for artesunate's activity in cancer cells. Curr. Cancer Drug Targets. 2009, 9, 72-80.
69. Ma, H.; Yao, Q.; Zhang, A.M.; Lin, S.;Wang, X.X.;Wu, L.; Sun, J.G.; Chen, Z.T. The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model. Molecules 2011, 16, 10556-10569.
70. Li, L.N.; Zhang, H.D.; Yuan, S.J.; Yang, D.X.;Wang, L.; Sun, Z.X. Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of -catenin and E-cadherin. Eur. J. Pharmacol. 2008, 588, 1-8.
71. Krusche, B.; Arend, J.; Efferth, T. Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo. Evid. Based Compl. Alternat. Med. 2013, 2013, 454783.
72. Ba, Q.; Duan, J.; Tian, J.Q.; Wang, Z.L.; Chen, T.; Li, X.G.; Wu, S.J.; Xiang, L.; Li, J.Q.; Chu, R.A.; et al. Dihydroartemisinin promotes angiogenesis during the early embryonic development of zebrafish. Acta Pharmacol. Sin. 2013, 34, 1101-1107.
73. Li, Q.; Weina, P.J. Severe embryotoxicity of artemisinin derivatives in experimental animals, but possibly safe in pregnant women. Molecules 2009, 15, 40-57.
74. Gomes, C.; Boareto, A.C.; Dalsenter, P.R. Clinical and non-clinical safety of artemisinin derivatives in pregnancy. Reprod. Toxicol. 2016, 65, 194-203.
75. Rutteman, G.R.; Erich, S.A.; Mol, J.A.; Spee, B.; Grinwis, G.C.; Fleckenstein, L.; London, C.A.; Efferth, T. Safety and efficacy field study of artesunate for dogs with non-resectable tumours. Anticancer Res. 2013, 33, 1819-1827.
76. Schmuck, G.; Roehrdanz, E.; Haynes, R.K.; Kahl, R. Neurotoxic mode of action of artemisinin. Antimicrob. Agents Chemother. 2002, 46, 821-827.
77. Krishna, S.; Ganapathi, S.; Ster, I.C.; Saeed, M.E.; Cowan, M.; Finlayson, C.; Kovacsevics, H.; Jansen, H.; Kremsner, P.G.; Efferth, T.; et al. A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. EBioMedicine 2015, 2, 82-90.
78. Berger, T.G.; Dieckmann, D.; Efferth, T.; Schultz, E.S.; Funk, J.O.; Baur, A.; Schuler, G. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol. Rep. 2005, 14, 1599-1603.
79. Zhang, Y.; Zhang, Y.; Ren, J. Application Value of Interventional Ultrasound in Treatment of Primary Hepatic. Mod. Diag. Treat. 2007, 18, 121.
80. Zhang, Z.Y.; Yu, S.Q.; Miao, L.Y.; Huang, X.Y.; Zhang, X.P.; Zhu, Y.P.; Xia, X.H.; Li, D.Q. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial. Zhong Xi Yi Jie He Xue Bao 2008, 6, 134-138.
81. Singh, N.P.; Panwar, V.K. Case report of a pituitary macro adenoma treated with artemether. Integr. Cancer Ther. 2006, 5, 391-394.
82. Huang, Y.; Li, H.; Peng, D.;Wang, Y.; Ren, Q.; Guo, Y. The production and exportation of artemisinin-derived drugs in China: current status and existing challenges. Malar. J. 2016, 15, 365.
83. Shen, J.; Sheng, X.; Chang, Z.; Wu, Q.; Wang, S.; Xuan, Z.; Li, D.; Wu, Y.; Shang, Y.; Kong, X.; et al. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep. 2014, 7, 180-193.
84. Ba, Q.; Zhou, N.; Duan, J.; Chen, T.; Hao, M.; Yang, X.; Li, J.; Yin, J.; Chu, R.;Wang, H. Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1. PLoS ONE 2012, 7, e42703.
85. Li, P.C.; Lam, E.; Roos, W.P.; Zdzienicka, M.Z.; Kaina, B.; Efferth, T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res. 2008, 68, 4347-4351.
86. Huang, C.; Ba, Q.; Yue, Q.; Li, J.; Li, J.; Chu, R.;Wang, H. Artemisinin rewires the protein interaction network in cancer cells: Network analysis, pathway identification, and target prediction. Mol. Biosyst. 2013, 9, 3091-3100.
87. Ochiuz, L.; Grigoras, C.; Popa, M.; Stoleriu, I.; Munteanu, C.; Timofte, D.; Profire, L.; Grigoras, A.G. Alendronate-Loaded Modified Drug Delivery Lipid Particles Intended for Improved Oral and Topical Administration. Molecules 2016, 21, 858.
88. Eltayeb, S.E.; Su, Z.; Shi, Y.; Li, S.; Xiao, Y.; Ping, Q. Preparation and optimization of transferrin-modifiedartemether lipid nanospheres based on the orthogonal design of emulsion formulation and physically electrostatic adsorption. Int. J. Pharm. 2013, 452, 321-332.
89. Gharib, A.; Faezizadeh, Z.; Mesbah-Namin, S.A.; Saravani, R. Preparation, characterization and in vitro efficacy of magnetic nanoliposomes containing the artemisinin and transferrin. DARU J. Pharm. Sci. 2014, 22, 44.
90. Jin, M.; Shen, X.; Zhao, C.; Qin, X.; Liu, H.; Huang, L.; Qiu, Z.; Liu, Y. In vivo study of effects of artesunate nanoliposomes on human hepatocellular carcinoma xenografts in nude mice. Drug Deliv. 2013, 20, 127-133.
91. Wang, S.; Wang, H.; Liang, W.; Huang, Y. An injectable hybrid nanoparticle-in-oil-in-water submicron emulsion for improved delivery of poorly soluble drugs. Nanoscale Res. Lett. 2012, 7, 219.
92. Yang, Y.; Zhang, X.;Wang, X.; Zhao, X.; Ren, T.;Wang, F.; Yu, B. Enhanced delivery of artemisinin and its analogues to cancer cells by their adducts with human serum transferrin. Int. J. Pharm. 2014, 467, 113-122.
93. Wang, Z.; Yu, Y.; Ma, J.; Zhang, H.; Zhang, H.;Wang, X.;Wang, J.; Zhang, X.; Zhang, Q. LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics. Mol. Pharm. 2012, 9, 2646-2657.
94. Chen, J.; Guo, Z.; Wang, H.B.; Zhou, J.J.; Zhang, W.J.; Chen, Q.W. Multifunctional mesoporous nanoparticles as pH-responsive Fe2+ reservoirs and artemisinin vehicles for synergistic inhibition of tumor growth. Biomaterials 2014, 35, 6498-6507.
95. Nguyen, H.T.; Tran, T.H.; Kim, J.O.; Yong, C.S.; Nguyen, C.N. Enhancing the in vitro anti-cancer efficacy of artesunate by loading into poly-D, L-lactide-co-glycolide (PLGA) nanoparticles. Arch. Pharm. Res. 2015, 38, 716-724.
96. McCarthy, D.J.; Malhotra, M.; O'Mahony, A.M.; Cryan, J.F.; O'Driscoll, C.M. Nanoparticlesand the Blood-BrainBarrier: Advancing from in-Vitro Models towards Therapeutic Significance. Pharm. Res. 2015, 32, 1161-1185.
97. Li, J.; Cai, P.; Shalviri, A.; Henderson, J.T.; He, C.; Foltz, W.D.; Prasad, P.; Brodersen, P.M.; Chen, Y.; DaCosta, R.; et al. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. ACS Nano. 2014, 8, 9925-9940.
98. Jose, S.; Anju, S.S.; Cinu, T.A.; Aleykutty, N.A.; Thomas, S.; Souto, E.B. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. Int. J. Pharm. 2014, 474, 6-13.
99. Goldstein, J.L. Creation and revelation: Two different routes to advancement in the biomedical sciences. Nat. Med. 2007, 13, 1151-1154.
100. Lai, H.C.; Singh, N.P.; Sasaki, T. Development of artemisinin compounds for cancer treatment. Investig. New Drugs. 2013, 31, 230-246.
101. Gupta, U.C.; Bhatia, S.; Garg, A.; Sharma, A.; Choudhary, V. Phase 0 clinical trials in oncology new drug development. Perspect. Clin. Res. 2011, 2, 13-22.
102. Zhao, Y.; Jiang, W.; Li, B.; Yao, Q.; Dong, J.; Cen, Y.; Pan, X.; Li, J.; Zheng, J.; Pang, X.; et al. Artesunate enhances radio sensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase. Int. Immunopharmacol. 2011, 11, 2039-2046.